ROCHE INNOVATION CENTER COPENHAGEN A/S;ENZON PHARMACEUTICALS INC.
发明人:
申请号：
IL20594410
公开号：
IL205944A
申请日:
2010.05.25
申请国别(地区):
IL
年份:
2015
代理人:
摘要：
The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.
